The Global AI Race: Technological Supremacy Or Collaborative Effort
Scottsdale’s Youtech Fuels National Growth with Local Talent Expansion
Youtech Deepens Texas Roots with Dallas-Area Talent Expansion Across Key Local Sectors
LaunchDarkly Introduces New Release Observability, AI Configurations, and Analytics Capabilities to Help Developers Innovate Faster Without the Risk
Best Debt Relief Programs for 2025 to Help You Get Out of Debt in USA
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral…
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a…
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual…
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity…
Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology…
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities…
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical…
LONDON, April 10, 2021 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…
Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in…
~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a…
ROCKVILLE, MD, April 10, 2021 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused…
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition Pan-cancer…
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells…
CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC)…
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1…
VANCOUVER, BC / ACCESSWIRE / April 10, 2021 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else”…
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best…